Literature DB >> 11014344

Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis.

P Barrera1, A Blom, P L van Lent, L van Bloois, J H Beijnen, N van Rooijen, M C de Waal Malefijt, L B van de Putte, G Storm, W B van den Berg.   

Abstract

OBJECTIVE: To assess whether intraarticular (IA) administration of clodronate liposomes results in local macrophage depletion in patients with rheumatoid arthritis (RA). Primary goals were to address both the immunohistologic and potential toxic effects of this approach. Moreover, the correlation between immunohistologic findings and clinical assessments of disease activity and cartilage damage were assessed.
METHODS: An open study was conducted in consecutive RA patients who were scheduled for knee joint replacement in our department. Synovial biopsy tissue was obtained from the knee joint at 2 weeks before and at the time of surgery. This protocol was controlled for safety and immunohistologic concordance in 6 patients. One week before surgery, 10 patients received a single IA dose of clodronate liposomes. Staining of synovial tissue for cell markers (CD68, CD14, CD3, CD38) and adhesion molecules (vascular cell adhesion molecule 1 [VCAM-1], intercellular adhesion molecule 1 [ICAM-1]) was assessed by 2 blinded observers. Local and systemic parameters of disease activity were measured before each intervention. Cartilage damage was scored using standard radiologic techniques at baseline and during surgery.
RESULTS: A single IA dose of clodronate liposomes significantly reduced the number of CD68-positive cells (P = 0.005) and the expression of ICAM-1 and VCAM-1 in the synovial lining (P = 0.013 and P = 0.039, respectively). The intervention did not affect fibroblast-like synoviocytes, T cells, or plasma cells. No immunohistologic changes were observed in the control group. The procedure was well tolerated. The levels of ICAM-1 and VCAM-1 in the sublining layers correlated with the extent of macroscopic synovitis (P < 0.0005 and P < 0.005, respectively). The expression of ICAM-1 and CD14 in the sublining correlated with the levels of C-reactive protein (P < 0.0005 and P < 0.01, respectively). Cartilage destruction was correlated only with the expression of CD68 in the sublining (P = 0.02).
CONCLUSION: A single IA administration of clodronate liposomes leads to macrophage depletion and decreased expression of adhesion molecules in the synovial lining in patients with longstanding RA. The procedure is well tolerated, and its therapeutic potential is currently under investigation. The expression of adhesion molecules in the sublining layers reflects ongoing inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014344     DOI: 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  63 in total

1.  Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model.

Authors:  Jun Li; Hui-Chen Hsu; PingAr Yang; Qi Wu; Hao Li; Laura E Edgington; Matthew Bogyo; Robert P Kimberly; John D Mountz
Journal:  Arthritis Rheum       Date:  2011-10-13

2.  Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis.

Authors:  Susanna Choi; Sungyong You; Donghyun Kim; Soo Youn Choi; H Moo Kwon; Hyun-Sook Kim; Daehee Hwang; Yune-Jung Park; Chul-Soo Cho; Wan-Uk Kim
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

3.  The cellular uptake and metabolism of clodronate in RAW 264 macrophages.

Authors:  H Mönkkönen; M J Rogers; N Makkonen; S Niva; S Auriola; J Mönkkönen
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 4.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

Review 5.  Development of macromolecular prodrug for rheumatoid arthritis.

Authors:  Fang Yuan; Ling-dong Quan; Liao Cui; Steven R Goldring; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

6.  Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

Authors:  P Barrera; L A Joosten; A A den Broeder; L B van de Putte; P L van Riel; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2001-07       Impact factor: 19.103

7.  Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.

Authors:  P L E M van Lent; P N Span; A W Sloetjes; T R D J Radstake; A W T van Lieshout; J J T M Heuvel; C G J Sweep; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2004-10-14       Impact factor: 19.103

8.  IRF5 controls both acute and chronic inflammation.

Authors:  Miriam Weiss; Adam J Byrne; Katrina Blazek; David G Saliba; James E Pease; Dany Perocheau; Marc Feldmann; Irina A Udalova
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

Review 9.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.

Authors:  Wiebke Ulbrich; Alf Lamprecht
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

10.  Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry.

Authors:  E Kunisch; R Fuhrmann; A Roth; R Winter; W Lungershausen; R W Kinne
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.